Abstract: The present invention relates to new oxazolidinone compounds of general formula (I) having antibiotic activity even against multiresistant bacterial strains (I).
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
March 20, 2018
Assignees:
UNIVERSITÀ DEGLI STUDI DI MILANO—BICOCCA, ISTITUTO EURO MEDITERRANEO DI SCIENZA E TECNOLOGIA
Inventors:
Rosario Musumeci, Clementina Elvezia Anna Cocuzza, Cosimo Gianluca Fortuna, Andrea Pace, Antonio Palumbo Piccionello
Abstract: The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.
Abstract: The disclosure provides for compositions and including fluopyram. The disclosure further provides for methods of increasing plant yield and reducing plant damage. Soil, seeds, plants, and plant parts treated with compositions described herein are also provided for by the disclosure.
Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
Type:
Grant
Filed:
October 24, 2013
Date of Patent:
February 13, 2018
Assignee:
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
February 6, 2018
Assignee:
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Inventors:
James T. Dalton, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy
Abstract: Increasing fertility in a mammal utilizes cationic steroidal antimicrobial (CSA) compounds and CSA-containing compositions. Such treatment in a mammal includes administering a formulation (e.g., lavage and/or infusion) including at least one CSA compound, or pharmaceutically acceptable salt thereof, to the reproductive structure(s) of the mammal (e.g., horse, dairy cow, human, etc.). The formulation may be applied topically as lavage and/or infusion to desired reproductive structures, such as the vagina, cervix, uterus, penis, or combinations thereof. The formulation may kill both planktonic and biofilm forms of sperm killing microbes, and may at least partially break up a microbial plaque or film located within any of the reproductive structures (e.g., the uterus).
Abstract: The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.
Type:
Grant
Filed:
June 6, 2016
Date of Patent:
January 2, 2018
Assignees:
Drexel University, Alliance Discovery, Inc.
Inventors:
Alessandro Fatatis, Joseph M. Salvino, Olimpia Meucci, Whitney L. Gladney
Abstract: Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.
Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
November 28, 2017
Assignee:
PHARMA MAR, S.A.
Inventors:
Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
Abstract: The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
November 28, 2017
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Michael J. Iadarola, Zoltan Olah, Laszlo Karai
Abstract: A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
November 14, 2017
Assignee:
Johnson Matthey Public Limited Company
Inventors:
Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Type:
Grant
Filed:
March 10, 2016
Date of Patent:
November 14, 2017
Assignee:
Pharmacyclics LLC
Inventors:
Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
Abstract: A lyophilized bendamustine composition consisting of bendamustine hydrochloride, an aqueous solvent, and optionally an excipient, and a method of preparation thereof for treating a condition in a subject are provided. The aqueous solvent includes, for example, water, an acid, a base, or a salt, etc. The excipient includes at least one cryoprotectant, for example, sucrose, trehalose, mannitol, etc. A pre-lyophilization bendamustine composition is lyophilized, for example, by freezing, primary drying, annealing, secondary drying, condensed cooling and evacuation at preset temperatures to obtain the lyophilized bendamustine composition as a cake, a powder, or a solid concentrate. The lyophilized bendamustine composition is free of a non-aqueous solvent. Reconstitution is performed by mixing the lyophilized bendamustine composition with an aqueous solvent for about 30 seconds to 300 seconds. The reconstituted bendamustine product containing about 0.2 wt % to about 2.
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Type:
Grant
Filed:
November 26, 2013
Date of Patent:
October 31, 2017
Assignee:
Pharmacyclics LLC
Inventors:
Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Type:
Grant
Filed:
February 26, 2016
Date of Patent:
October 31, 2017
Assignee:
Pharmacyclics LLC
Inventors:
Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
Abstract: Bicyclic compounds for decreasing the expression of bacterial virulence factors thereby preventing, mitigating, or treating bacterial infection are provided.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
October 17, 2017
Assignee:
TRUSTEES OF DARTMOUTH COLLEGE
Inventors:
F. Jon Kull, Ronald K. Taylor, Gordon W. Gribble, Evans O. Onyango, Anne R. Kelley
Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Type:
Grant
Filed:
March 16, 2016
Date of Patent:
September 26, 2017
Assignee:
ABIDE THERAPEUTICS, INC.
Inventors:
Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Olivia D. Weber, Dong-Hui Wang
Abstract: The present invention relates to a composition comprising at least 3 different diols, wherein said diols have the general structure (CH2)nH2O2, wherein n is the number of CH2 and being between 3 to 10, in a total amount of from about 0.1 to about 50% (v/v), a method for producing the composition and its use, such as in therapy. The composition may be a pharmaceutical, cosmetic, antimicrobial or preservative composition. The composition is useful in inactivating microorganisms or preventing their growth.
Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
September 5, 2017
Assignee:
Pharma Mar, S.A.
Inventors:
Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez